Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Martín, M. (Miguel) | - |
dc.creator | Guerrero-Zotano, A. (Angel) | - |
dc.creator | Montero, Á. (Ángel) | - |
dc.creator | Jara, C. (Carlos) | - |
dc.creator | Filipovich, E. (Elena) | - |
dc.creator | Rojo-Todo, F. (Federico) | - |
dc.creator | Moreno, F. (Fernando) | - |
dc.creator | García-Sáenz, J.Á. (José Ángel) | - |
dc.creator | Alés, J.E. (José Enrique) | - |
dc.creator | Chacón, J.I. (José Ignacio) | - |
dc.creator | Cruz, J. (Josefina) | - |
dc.creator | Gimenez, J. (Julia) | - |
dc.creator | Cruz-Merino, L. (Luis) de la | - |
dc.creator | Algara, M. (Manel) | - |
dc.creator | Santisteban, M. (Marta) | - |
dc.creator | López-Tarruella, S. (Sara) | - |
dc.date.accessioned | 2023-05-23T07:26:17Z | - |
dc.date.available | 2023-05-23T07:26:17Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Martín, M. (Miguel); Guerrero-Zotano, A. (Angel); Montero, Á. (Ángel); et al. "GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain". The Oncologist. 25 (9), 2020, e1339 - e1345 | es |
dc.identifier.issn | 1083-7159 | - |
dc.identifier.uri | https://hdl.handle.net/10171/66323 | - |
dc.description.abstract | Breast cancer (BC) is the most common cancer in women in Spain. During the COVID-19 pandemic caused by the SARSCoV-2 virus, patients with BC still require timely treatment and follow-up; however, hospitals are overwhelmed with infected patients and, if exposed, patients with BC are at higher risk for infection and serious complications if infected. Thus, health care providers need to evaluate each BC treatment and in-hospital visit to minimize pandemic-associated risks while maintaining adequate treatment efficacy. Here we present a set of guidelines regarding available options for BC patient management and treatment by BC subtype in the context of the COVID-19 pandemic. Owing to the lack of evidence about COVID-19 infection, these recommendations are mainly based on expert opinion, medical organizations’ and societies’ recommendations, and some published evidence. We consider this a useful tool to facilitate medical decision making in this health crisis situation we are facing. | es_ES |
dc.description.sponsorship | Miguel Martín: Roche, PUMA, Novartis (RF), AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Daiichi Sankyo, Pfizer (C/A), AstraZeneca, Amgen, Roche/ Genentech, Novartis, Pfizer (H); Fernando Moreno: Pfizer, Merck Sharp & Dohme, Novartis, Roche/Genentech, AstraZeneca (C/A), Pfizer, Roche (H), Roche/Genentech, Novartis, Pfizer (travel support), Pfizer, AstraZeneca (RF [to institution]); Jose Angel García Sáenz: Novartis, Celgene, Eli Lilly, EISAI, AstraZeneca (H), Novartis, Roche, Pfizer (travel support), Pfizer, AstraZeneca (RF [to institution]); José Ignacio Chacón: Roche Farma, Pfizer, Eisai, Eli Lilly, Novartis (H); Josefina Cruz: Glaxo, AstraZeneca, Roche, Novartis, PharmaMar, Eisai, Eli Lilly, Celgene, Astellas, Amgen, Pfizer (H), AstraZeneca, Roche, Novartis, PharmaMar, Eisai, Eli Lilly, Celgene, Astellas, Amgen, Glaxo, Pfizer (C/A); Luis de la Cruz Merino: MSD-Merck, Roche Farma, Bristol-Myers Squibb, Pierre-Fabré, Amgen, Novartis (C/A), MSD-Merck, Roche Farma, Bristol-Myers Squibb, Amgen (H), Bristol-Myers Squibb, Roche Farma, MSD-Merck, Celgene (RF). The other authors indicated no financial relationships. (C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/ inventor/patent holder; (SAB) Scientific advisory board | es_ES |
dc.language.iso | eng | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Breast cancer | es_ES |
dc.subject | Pandemic | es_ES |
dc.subject | COVID-19 | es_ES |
dc.subject | SARS-CoV-2 | es_ES |
dc.subject | Expert recommendations | es_ES |
dc.title | GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. | es_ES |
dc.identifier.doi | 10.1634/theoncologist.2020-0363 | - |
dadun.citation.endingPage | e1345 | es_ES |
dadun.citation.number | 9 | es_ES |
dadun.citation.publicationName | The Oncologist | es_ES |
dadun.citation.startingPage | e1339 | es_ES |
dadun.citation.volume | 25 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.